Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

C. AND SUBSIDIARIES

Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(Unaudited)

Three Months Ended

September 30,

2007 2006

GAAP NET INCOME (LOSS) $(306,763) $95,741

Sales adjustments - (13,273)(6)

Cost of sales adjustments 22,255 (1) 20,804 (1)

Research and development adjustments 15,000 (2) - (8)

Selling, general and administrative

adjustments - 2,000 (7) (8)

Settlement reserve 369,000 (3) -

Gain on extinguishment of debt (5,319)(4) -

Income taxes (21,693)(5) (1,278)(5) (8)

379,243 8,253

ADJUSTED NET INCOME $72,480 $103,994

BASIC ADJUSTED INCOME PER COMMON SHARE $1.08 $1.71

DILUTED ADJUSTED INCOME PER COMMON SHARE $0.92 $1.55

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 66,931 60,762

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 79,030 67,072 Notes to Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets.

(2) To exclude the recognition of a milestone related to the FDA's

acceptance of our NDA filing for TREANDA(R) (bendamustine HCl).

(3) To exclude the additional reserve established for the agreement in

principle reached with the U.S. Attorney's Office in Philadelphia.

(
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... April 13 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... months ended February 28, 2009. All dollar amounts referenced herein ... 28, 2009, our cash and cash equivalents totaled $7.3 million, ... incurred a net loss for the three months ended February ...
... Decisions Day, your choice in times of despair HOUSTON, ... .( www.usoncology.com ), supporting the nation,s foremost ... and manufacturers to advance cancer care in America, is ... National Healthcare Decisions Day ( www.nationalhealthcaredecisionsday.org ...
... Kan., April 13 Kansas State University ... thin material.Vikas Berry, assistant professor of chemical engineering, is ... developed carbon material that is only a single atom ... to the next level," Berry said. "Discovered only four ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9US Oncology Encourages Your Right to Decide 2US Oncology Encourages Your Right to Decide 3Connecting Materials Science With Biology, K-State Engineers Create DNA Sensors That Could Identify Cancer Using Material Only One Atom Thick 2Connecting Materials Science With Biology, K-State Engineers Create DNA Sensors That Could Identify Cancer Using Material Only One Atom Thick 3
(Date:4/24/2014)... Carolina State University and the University of North Carolina ... that could help identify arterial plaque that is at ... or stroke. , At issue is the plaque that ... of plaque are deemed "vulnerable," meaning that they are ... cause heart attack or stroke. , "Existing state-of-the-art technologies ...
(Date:4/24/2014)... puts out a welcome mat to bacteria seeking to invade, ... study published this week in the Proceedings of the ... battle between microbe and host that researchers can exploit to ... oft-studied plant Arabidopsis puts out a molecular signal ... a hostile army were unknowingly passing by a castle, and ...
(Date:4/23/2014)... release is available in French and German . ... or female? In humans and other mammals, the difference between sexes ... It is present only in males, where the two sexual chromosomes ... the Y is ultimately responsible for all the morphological and physiological ... been the case. A very long time ago, the X and ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3
... 16, 2010 VaxTrac announced today that it has ... Bill & Melinda Gates Foundation. The grant will support ... Thomas, Executive Director, titled "VaxTrac Pilot Program 1 Narnaul, ... grants announced by the Gates Foundation in the fifth ...
... published Friday in the leading scientific journal, Cell , ... cells using skin cells from four individuals with Rett syndrome. ... Dr. Alysson Muotri at the University of California, San Diego--a ... The article, titled ,A Model for Neural Development and Treatment ...
... the greater Himalayan region are retreating slowly, development agencies ... prepare for the many ways glacier melt is expected ... Programs that integrate health, education, the environment and social ... report states. "The extremely high altitudes and sheer mass ...
Cached Biology News:VaxTrac Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2Researchers 'grow Rett syndrome' in a Petri dish 2Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5
Sterile, individually wrapped, 4mm Cuvettes...
... an enhanced form of Tobacco Etch Virus ... active, and significantly more stable than native ... Protease specifically recognizes a seven amino acid ... it useful for removing affinity tags from ...
... a fully flexible quadrupole MS detector optimized ... HPLC, 1-D and 2-D LC, as well ... incorporates a drying gas system to create ... especially for low-to-medium polarity compounds, while providing ...
S-100A10 (H-80)...
Biology Products: